Aldafermin Market

“Aldafermin Market Size, Forecast, and Emerging Insight − 2032” report offers an in-depth analysis of both market and emerging insights regarding Aldafermin for the treatment of Non-alcoholic Steatohepatitis (NASH) in Japan. A detailed picture of the Aldafermin for NASH in Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the Aldafermin for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Aldafermin market forecast analysis for NASH in Japan, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary

Aldafermin (previously NGM282) is an engineered variant of the human hormone FGF19, in development as a once-daily injection for treating NASH. FGF19 is a highly specific and potent regulator of liver fat metabolism and bile acid synthesis responsible for some of the beneficial effects of gastric bypass surgery on NASH.

Phase IIb ALPINE 2/3 trial evaluating aldafermin in patients with F2/F3 NASH did not meet its primary endpoint. Hence, the company decided to suspend further development of aldafermin in patients with F2/F3 NASH. However, they continued, and completed enrollment in Phase IIb ALPINE 4 clinical trial of aldafermin in patients with compensated cirrhosis due to NASH. Topline data from ALPINE 4, the Phase IIb trial of aldafermin in patients with F4 NASH, have been announced by the company in May 2023.

NGM is seeking a partner to continue further development of aldafermin.

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the Aldafermin description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on Aldafermin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Aldafermin research and development activities in NASH across Japan.
• The report also covers the patents information with expiry timeline around Aldafermin.
• The report contains forecasted sales of Aldafermin for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for Aldafermin in NASH.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Aldafermin Analytical Perspective by DelveInsight

• In-depth Aldafermin Market Assessment

This report provides a detailed market assessment of Aldafermin for Non-alcoholic Steatohepatitis (NASH) in Japan. This segment of the report provides forecasted sales data from 2029 to 2032.

• Aldafermin Clinical Assessment

The report provides the clinical trials information of Aldafermin for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Aldafermin dominance.
• Other emerging products for NASH are expected to give tough market competition to Aldafermin and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Aldafermin in NASH.
• Our in-depth analysis of the forecasted sales data of Aldafermin from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Aldafermin in NASH. 

Key Questions

• What is the product type, route of administration and mechanism of action of Aldafermin?
• What is the clinical trial status of the study related to Aldafermin in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Aldafermin development?
• What are the key designations that have been granted to Aldafermin for NASH?
• What is the forecasted market scenario of Aldafermin for NASH?
• What are the forecasted sales of Aldafermin in Japan?  
• What are the other emerging products available and how are these giving competition to Aldafermin for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?